BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2025 10:16:43 AM | Browse: 81 | Download: 538
 |
Received |
|
2024-12-20 03:25 |
|
Peer-Review Started |
|
2024-12-20 03:26 |
|
First Decision by Editorial Office Director |
|
2025-01-10 09:46 |
|
Return for Revision |
|
2025-01-10 09:46 |
|
Revised |
|
2025-01-15 10:03 |
|
Publication Fee Transferred |
|
2025-01-17 14:37 |
|
Second Decision by Editor |
|
2025-02-25 02:50 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-25 10:32 |
|
Articles in Press |
|
2025-02-25 10:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-14 01:44 |
|
Publish the Manuscript Online |
|
2025-03-26 10:16 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Feng-Ling Huang, Min Luo, Zhen-Mei He, Yong-Qi Shen and Guan-Da Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Chinese Medicine Administration Bureau of Guangxi Zhuang Autonomous Region |
GXZYB20220472 |
|
| Corresponding Author |
Guan-Da Liu, MD, Department of Pharmacology and Clinical Pharmacy, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, No. 10 Huadong Road, Nanning 530000, Guangxi Zhuang Autonomous Region, China. rkjp2024@163.com |
| Key Words |
Pulmonary lymphoepithelioma-like carcinoma; Epstein-Barr virus; Anlotinib; Toripalimab; Case report |
| Core Tip |
We report a case of a 38-year-old man who was diagnosed with right pulmonary lymphoepithelioma-like carcinoma (PLELC). Chest computed tomography (CT) revealed a mass in the medial segment of the middle lobe of the right lung, with lymph node metastasis in the mediastinum and right hilum of the lung. CT-guided lung tumor biopsy was performed and the postoperative pathological examination combined with immune phenotype analysis and in situ hybridization confirmed PLELC. Standard molecular testing for patients with non-small cell lung cancer was negative and programmed cell death ligand-1 expression was about 2%. However, the patient declined radiotherapy and chemotherapy treatment. Consequently, immunotherapy was administered, which included toripalimab 240 mg on day 1 and anlotinib 10 mg on days 1-14 for 10 cycles, followed by a maintenance dose of anlotinib 10 mg daily every 3 weeks. As a result, his progression-free survival reached 48 months. PLELC is a rare primary epithelial lung cancer. Currently, there is no standard treatment for PLELC. A combination of toripalimab and anlotinib may benefit patients with advanced diseases who have not received systematic anti-tumor therapy. However, its long-term efficacy requires further comprehensive research and validation. |
| Publish Date |
2025-03-26 10:16 |
| Citation |
Huang FL, Luo M, He ZM, Shen YQ, Liu GD. Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma: A case report. World J Clin Oncol 2025; 16(4): 104413 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i4/104413.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i4.104413 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
